CD80 and glioblastoma: Circulating miRNAs are increasingly gaining attention as screening biomarkers in central nervous system (CNS) diseases.11 In this work, identified candidates warrant monitoring in larger cohort studies to investigate their biomarker value, i.e., miR-16, also investigated as a biomarker for glioblastoma,12 and CD86 (CD80), which has been implicated in progressive inflammatory myelopathy.13